Genentech Inc. will get its day — actually two — in front of the Food and Drug Administration to plead its case for keeping Avastin as a treatment for women with metastatic breast cancer.
The hearing, scheduled for June 28-29, comes after the FDA in December said it would yank its conditional approval of Avastin for use by women with breast cancer that has spread to other parts of the body.
No comments:
Post a Comment